Annual Cash & Cash Equivalents
$6.70 M
-$30.45 M-81.97%
December 31, 2023
Summary
- As of February 26, 2025, ONCT annual cash & cash equivalents is $6.70 million, with the most recent change of -$30.45 million (-81.97%) on December 31, 2023.
- During the last 3 years, ONCT annual cash & cash equivalents has fallen by -$110.04 million (-94.26%).
- ONCT annual cash & cash equivalents is now -94.40% below its all-time high of $119.55 million, reached on December 31, 2006.
Performance
ONCT Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$13.08 M
+$6.70 M+104.94%
September 30, 2024
Summary
- As of February 26, 2025, ONCT quarterly cash and cash equivalents is $13.08 million, with the most recent change of +$6.70 million (+104.94%) on September 30, 2024.
- Over the past year, ONCT quarterly cash and cash equivalents has stayed the same.
- ONCT quarterly cash and cash equivalents is now -89.81% below its all-time high of $128.31 million, reached on March 31, 2008.
Performance
ONCT Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ONCT Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -82.0% | 0.0% |
| 3 y3 years | -94.3% | +16.3% |
| 5 y5 years | -76.3% | +16.3% |
ONCT Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -92.6% | at low | -85.6% | +104.9% |
| 5 y | 5-year | -94.3% | at low | -88.8% | +104.9% |
| alltime | all time | -94.4% | +334.3% | -89.8% | +153.7% |
Oncternal Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $13.08 M(+104.9%) |
| Jun 2024 | - | $6.38 M(-0.2%) |
| Mar 2024 | - | $6.40 M(-4.5%) |
| Dec 2023 | $6.70 M(-82.0%) | $6.70 M(-55.1%) |
| Sep 2023 | - | $14.93 M(-5.7%) |
| Jun 2023 | - | $15.83 M(+40.8%) |
| Mar 2023 | - | $11.24 M(-69.7%) |
| Dec 2022 | $37.14 M(-59.1%) | $37.14 M(-47.4%) |
| Sep 2022 | - | $70.63 M(-10.5%) |
| Jun 2022 | - | $78.90 M(-4.0%) |
| Mar 2022 | - | $82.16 M(-9.5%) |
| Dec 2021 | $90.77 M(-22.2%) | $90.77 M(-6.8%) |
| Sep 2021 | - | $97.38 M(-6.1%) |
| Jun 2021 | - | $103.66 M(-6.8%) |
| Mar 2021 | - | $111.21 M(-4.7%) |
| Dec 2020 | $116.74 M(+482.2%) | $116.74 M(+449.1%) |
| Sep 2020 | - | $21.26 M(+27.9%) |
| Jun 2020 | - | $16.62 M(+3.7%) |
| Mar 2020 | - | $16.02 M(-20.1%) |
| Dec 2019 | $20.05 M(-29.0%) | $20.05 M(-13.2%) |
| Sep 2019 | - | $23.10 M(-19.0%) |
| Jun 2019 | - | $28.52 M(+35.7%) |
| Mar 2019 | - | $21.01 M(-25.6%) |
| Dec 2018 | $28.26 M(+78.7%) | $28.26 M(+22.4%) |
| Sep 2018 | - | $23.09 M(+39.8%) |
| Jun 2018 | - | $16.51 M(+10.4%) |
| Mar 2018 | - | $14.96 M(-5.4%) |
| Dec 2017 | $15.82 M(+77.5%) | $15.82 M(-70.4%) |
| Sep 2017 | - | $53.43 M(+936.3%) |
| Jun 2017 | - | $5.16 M(-33.7%) |
| Mar 2017 | - | $7.77 M(-12.8%) |
| Dec 2016 | $8.91 M(-36.6%) | $8.91 M(+8.2%) |
| Sep 2016 | - | $8.24 M(-13.9%) |
| Jun 2016 | - | $9.57 M(-20.6%) |
| Mar 2016 | - | $12.06 M(-14.2%) |
| Dec 2015 | $14.06 M(-21.4%) | $14.06 M(+19.1%) |
| Sep 2015 | - | $11.80 M(-17.6%) |
| Jun 2015 | - | $14.32 M(+1.1%) |
| Mar 2015 | - | $14.16 M(-20.8%) |
| Dec 2014 | $17.88 M(+23.1%) | $17.88 M(+85.7%) |
| Sep 2014 | - | $9.63 M(-13.9%) |
| Jun 2014 | - | $11.18 M(-50.2%) |
| Mar 2014 | - | $22.43 M(+54.4%) |
| Dec 2013 | $14.53 M | $14.53 M(-24.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2013 | - | $19.28 M(-31.7%) |
| Jun 2013 | - | $28.25 M(-21.8%) |
| Mar 2013 | - | $36.14 M(-24.8%) |
| Dec 2012 | $48.04 M(-24.6%) | $48.04 M(+24.0%) |
| Sep 2012 | - | $38.73 M(-18.1%) |
| Jun 2012 | - | $47.32 M(-15.4%) |
| Mar 2012 | - | $55.91 M(-12.3%) |
| Dec 2011 | $63.74 M(+9.6%) | $63.74 M(-13.0%) |
| Sep 2011 | - | $73.30 M(-11.1%) |
| Jun 2011 | - | $82.42 M(+92.6%) |
| Mar 2011 | - | $42.79 M(-26.5%) |
| Dec 2010 | $58.18 M(+44.7%) | $58.18 M(+231.5%) |
| Sep 2010 | - | $17.55 M(-12.2%) |
| Jun 2010 | - | $19.99 M(-32.4%) |
| Mar 2010 | - | $29.58 M(-26.5%) |
| Dec 2009 | $40.22 M(-57.9%) | $40.22 M(-15.3%) |
| Sep 2009 | - | $47.46 M(-29.7%) |
| Jun 2009 | - | $67.50 M(-15.8%) |
| Mar 2009 | - | $80.17 M(-16.1%) |
| Dec 2008 | $95.51 M(-4.7%) | $95.51 M(-6.2%) |
| Sep 2008 | - | $101.78 M(-9.9%) |
| Jun 2008 | - | $112.94 M(-12.0%) |
| Mar 2008 | - | $128.31 M(+28.1%) |
| Dec 2007 | $100.18 M(-16.2%) | $100.18 M(+10.2%) |
| Sep 2007 | - | $90.94 M(-10.9%) |
| Jun 2007 | - | $102.03 M(-8.4%) |
| Mar 2007 | - | $111.43 M(-6.8%) |
| Dec 2006 | $119.55 M(+61.5%) | $119.55 M(+168.3%) |
| Sep 2006 | - | $44.55 M(-19.8%) |
| Jun 2006 | - | $55.56 M(-14.9%) |
| Mar 2006 | - | $65.28 M(-11.8%) |
| Dec 2005 | $74.01 M(+14.7%) | $74.01 M(+95.8%) |
| Sep 2005 | - | $37.81 M(-21.4%) |
| Jun 2005 | - | $48.08 M(-13.5%) |
| Mar 2005 | - | $55.58 M(-13.9%) |
| Dec 2004 | $64.53 M(+336.9%) | $64.53 M(-15.2%) |
| Sep 2004 | - | $76.09 M(-6.6%) |
| Jun 2004 | - | $81.44 M(+1.0%) |
| Mar 2004 | - | $80.62 M(+445.9%) |
| Dec 2003 | $14.77 M(+65.5%) | $14.77 M |
| Dec 2002 | $8.93 M(+1.0%) | - |
| Dec 2001 | $8.83 M(+231.2%) | - |
| Dec 2000 | $2.67 M(+73.0%) | - |
| Dec 1999 | $1.54 M | - |
FAQ
- What is Oncternal Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Oncternal Therapeutics?
- What is Oncternal Therapeutics annual cash & cash equivalents year-on-year change?
- What is Oncternal Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Oncternal Therapeutics?
- What is Oncternal Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Oncternal Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of ONCT is $6.70 M
What is the all time high annual cash & cash equivalents for Oncternal Therapeutics?
Oncternal Therapeutics all-time high annual cash & cash equivalents is $119.55 M
What is Oncternal Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, ONCT annual cash & cash equivalents has changed by -$30.45 M (-81.97%)
What is Oncternal Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ONCT is $13.08 M
What is the all time high quarterly cash and cash equivalents for Oncternal Therapeutics?
Oncternal Therapeutics all-time high quarterly cash and cash equivalents is $128.31 M
What is Oncternal Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, ONCT quarterly cash and cash equivalents has changed by $0.00 (0.00%)